Charles River Laboratories

4Q Revenues: $291.0 million (+3%)

4Q Earnings: $27.1 million (loss of $342.4 million 4Q10)

FY Revenues: $1.1 billion (+1%)

FY Earnings: $115.5 million (loss of $334.1 million FY10)

Comments: Sales for the Research Models and Services (RMS) segment were $182.4 million in 4Q11 (+8%), and $705.4 million for the year (+6%). Sales from the Preclinical Services (PCS) segment in the quarter were $108.5 million (-4%), due to shorter term, less complex studies, as well as fewer GLP safety assessment studies. For the year PCS sales were $437.2 million (-6%). In 4Q10 results included non-cash goodwill and asset impairments of $395.0 million, and for the year, results included a $30.0 million fee related to the termination of a proposed acquisition.